Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
68 hedge funds and large institutions have $27.6M invested in Elevation Oncology in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 28 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
16% less funds holding
Funds holding: 81 → 68 (-13)
17.7% less ownership
Funds ownership: 95.41% → 77.71% (-18%)
46% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 28
80% less capital invested
Capital invested by funds: $140M → $27.6M (-$113M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $31K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.17M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$4.5M |
| 3 |
Renaissance Technologies
New York
|
+$2.65M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.52M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.71M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$6.57M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$4.81M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.54M |
ELEV Hedge Fund Activity: Q3 2024 in Review
68 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q3 2024, worth a combined $27.6M — down 80% from $140M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ELEV and 15 opened new positions — a net loss of 13 holders — while 16 trimmed existing stakes and 24 added.
The largest buyer was Goldman Sachs, adding an estimated $5.17M. The largest seller was Logos Global Management, exiting entirely with an estimated $10.4M sold.
- 68 institutional investors held Elevation Oncology (ELEV) as of Q3 2024, down from 81 in Q2 2024.
- Funds reported $27.6M of Elevation Oncology stock for Q3 2024, down 80% quarter-over-quarter.
- 15 funds opened new Elevation Oncology positions in Q3 2024 and 28 closed out, a net change of -13 holders.
- The largest Elevation Oncology buyer in Q3 2024 was Goldman Sachs, an estimated $5.17M added.
- The largest Elevation Oncology seller in Q3 2024 was Logos Global Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2024.